Allergan Aesthetics, a division of AbbVie, reports that rapid medical weight loss is changing facial aesthetic trends. Patients who lose significant weight now seek more facial aesthetic care than before. Many have never visited an aesthetic clinic prior to losing weight. Weight loss prompts new facial concerns Allergan’s analysis shows that medical weight loss (MWL) treatments raise concerns about facial ...
Allergan Aesthetics reveals insights on medical weight loss (MWL) and evolving patient expectations. The data shows how weight-loss treatments influence demand for aesthetic procedures. Medical weight loss treatments gain attention MWL programmes, including GLP-1 medications, help patients achieve significant weight reductions under medical supervision. These treatments are driving a new demographic seeking aesthetic care. Many patients experience midface volume loss, ...
Botulinum toxin and dermal fillers remain two of the highest-demand minimally invasive aesthetic procedures in India. However, practitioners continue to report significant patient confusion between the two modalities. According to Dr Akanksha Agarwal, Founder-Director and Head of Aesthetic Services at the Centre for Aesthetics, Gurgaon, Botox and fillers address entirely different anatomical concerns. They should not be positioned as interchangeable ...
The global dermal fillers market will expand steadily over the next decade. Revenue will rise from about US$ 6.8 billion in 2026 to US$ 9.9 billion by 2036. Hence growing at an average annual rate of 3.2 percent. This growth reflects rising demand for minimally invasive cosmetic treatments and broader interest in facial aesthetics among diverse age groups. Social media ...
Coherent Market Insights predicts the global dermal fillers market will grow from USD 5.12 billion in 2025 to USD 10.97 billion by 2032. The forecast highlights the market’s strong growth momentum over the next decade. The 11.5% CAGR underscores rising demand for minimally invasive aesthetics, greater cosmetic awareness, and rapid advancements in filler technology. Rising demand for non-surgical facial ...
Galderma showcased significant updates across its dermatology portfolio at the 2025 American Academy of Dermatology (AAD) Annual Meeting. The company reinforces its leadership commitment in dermatology innovation with 22 scientific presentations, including two oral e-posters. Nemluvio Nemolizumab (Nemulizumab), Galderma’s treatment for prurigo nodularis and atopic dermatitis, was a key focus at AAD 2025. A new oral presentation showcases Nemluvio’s efficacy ...